Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.

Clivatuzumab 对胰腺导管腺癌（PDAC）表现出高度特异性，对正常及良性的非肿瘤胰腺组织几乎不表现出反应。尽管它对其他某些器官（如胃、结肠和肺）的腺癌反应有限（大约10%的样本）[1]。